Claims for Patent: 8,101,743

Summary for Patent: 8,101,743

Title:	Modulation of transthyretin expression
Abstract:	Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
Inventor(s):	Brown-Driver; Vickie L. (Solana Beach, CA), Jain; Ravi (Fremont, CA)
Assignee:	Isis Pharmaceuticals, Inc. (Carlsbad, CA)
Application Number:	12/273,731
Patent Claims:	1. A compound comprising a modified oligonucleotide consisting of 20 linked nucleosides, wherein said modified oligonucleotide comprises a nucleobase sequence that is 100% complementary to SEQ ID NO: 4 as measured over the entirety of said modified oligonucleotide, wherein said nucleobase sequence has at least 95% identity to SEQ ID NO: 74, and wherein said modified oligonucleotide comprises: a gap segment consisting of linked deoxynucleosides; a 5' wing segment consisting of linked nucleosides; and a 3' wing segment consisting of linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar. 2. The compound of claim 1, wherein the modified sugar is a 2'-O-methoxyethyl or a 4'-(CH.sub.2).sub.n-O-2' bridge, wherein n is 1 or 2. 3. The compound of claim 1, wherein at least one internucleoside linkage is a phosphorothioate internucleoside linkage. 4. The compound of claim 1, wherein the modified oligonucleotide comprises at least one 5-methylcytosine. 5. The compound of claim 1, wherein the modified sugar is a bicyclic sugar. 6. The compound of claim 1, wherein the modified oligonucleotide comprises: a gap segment consisting of ten linked deoxynucleosides; a 5' wing segment consisting of five linked nucleosides; and a 3' wing segment consisting of five linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each of said nucleosides of each of the wing segments comprises a 2'-O-methoxyethyl sugar, wherein each cytosine of said modified oligonucleotide is a 5-methylcytosine, and wherein each internucleoside linkage of said modified oligonucleotide is a phosphorothioate linkage. 7. A composition comprising: the compound of claim 1, or a salt thereof and, a pharmaceutically acceptable carrier or diluent. 8. The compound of 1, wherein the modified sugar is a sugar mimetic. 9. The compound of claim 3, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.